康寧傑瑞製藥(09966.HK)就新藥與先聲藥業及思路迪醫藥訂合作協議
康寧傑瑞製藥(09966.HK)公布,江蘇康寧傑瑞、先聲藥業及思路迪醫藥於2020年3月30日訂立一份合作協議,授予於中國(除香港特別行政區、澳門特別行政區及台灣地區之外)內進行KN035的腫瘤適應症的獨家市場推廣權及於中國大陸內對外許可或轉讓下的優先授讓權。
公司指,KN035是重組人源化抗PD-L1單域抗體Fc融合蛋白,由公司自主研發,2016年起與思路迪醫藥共同開發,有望成為全球首個上市的通過皮下注射給藥的PD-1/PD-L1抗體。(el/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.